Empagliflozin in heart failure with preserved ejection fraction: from randomized trials to real-world evidence
In real-world elderly and comorbid HFpEF population, empagliflozin was well tolerated and associated with improvements in congestion and functional status, supporting the external validity of randomised trial findings.
Authors
- Evelyne Meekers (ORCID: https://orcid.org/0000-0002-0204-0132)
- Pieter Martens (ORCID: https://orcid.org/0000-0002-6036-2113)
- Amrit Singh (ORCID: https://orcid.org/0000-0002-7475-1646)
- Philippe B. Bertrand (ORCID: https://orcid.org/0000-0001-6324-6874)
- Valérie F. E. D. Smolders (ORCID: https://orcid.org/0000-0002-9863-7581)
- Sebastiaan Dhont (ORCID: https://orcid.org/0000-0002-5615-3191)
- Wilfried Müllens (ORCID: https://orcid.org/0000-0001-9995-8590)
- Bram Swinnen
- Kwinten Vandebergen
Institutions
- Ziekenhuis Oost-Limburg (BE)
- Hasselt University (BE)
Publication Details
- Journal
- Acta cardiologica. Supplementum
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1080/00015385.2025.2538386
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29